Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 14
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
CEPO906A2303
NCT00262990
2.
EPO906 in Patients With Late Stage Non-Small-Cell Lung Cancer (NSCLC)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Pharmaceutical / Industry
CEPO906A 2209
NCT00088127
3.
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
3c-03-19
NCT00159484
4.
Study of Patupilone in Patients With Brain Metastasis From Non-Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
CEPO906A2227
NCT00219297
5.
Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Other
OZM-005/CEPO906A2402
Protocol number CEP0906A2402, OZM-005, NCT00407251
6.
Efficacy and Safety of Patupilone in Men (=18 Years) With Metastatic Hormone Refractory Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
CEPO906A2229
NCT00411528
Last Modified:
6/27/2007
 
First Published:
3/16/2007
7.
Phase II Study of Epothilone B in Patients With CNS Metastases Secondary to Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI
CASE-5106
CASE-IRB-5106-CC185, CASE 5106, NCT00450866, MSKCC-07036
8.
EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and over
Other
03C.275
NCT00328458
9.
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Biomarker/Laboratory analysis, Treatment
Active
18 and over
Pharmaceutical / Industry
CEPO906A2121
NCT00420524
10.
Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Biomarker/Laboratory analysis, Treatment
Active
18 and over
Pharmaceutical / Industry
CEPO906A2123
NCT00420615
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute